CompletedPHASE2, PHASE3NCT00282724
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis
Studying Autosomal recessive congenital ichthyosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stiefel, a GSK Company
- Principal Investigator
- Koen van Rossem, MD, PhDBarrier Therapeutics/ Stiefel, a GSK Company
- Intervention
- Liarozole(drug)
- Enrollment
- 98 enrolled
- Eligibility
- 14 years · All sexes
- Timeline
- 2006 – 2007
Study locations (16)
- Academisch Ziekenhuis Vrije Universiteit Brussel, Brussels, Belgium
- Geel, Geel, Belgium
- Hôpital Saint-Justine, Montreal, Canada
- Newlab Clinical Research Inc., St. John's, Canada
- Instituto Dermatologico, Santo Domingo, Dominican Republic
- Hôtel Dieu CHU, Nantes, France
- Tomesa Fachklinik, Bad Salzschlirf, Germany
- Dueren, Düren, Germany
- Otto-von-Guericke-Universität, Magdeburg, Germany
- University Hospital Muenster, Münster, Germany
- Fondazione Policlinico Mangiagalli e Regina Elena, Milan, Italy
- Istituto Dermopatico dell'Immacolata, Rome, Italy
- Academisch Ziekenhuis Maastricht, Maastricht, Netherlands
- University Hospital Rotterdam, Rotterdam, Netherlands
- Rikshospitalet Universitetsklinikk, Oslo, Norway
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00282724 on ClinicalTrials.gov